Increasing high-density lipoprotein cholesterol: An update on fenofibrate

American Journal of Cardiology

Volumn 88, Issue 12 SUPPL., 2001, Pages 30-36

  Després, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ATORVASTATIN; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAVASTATIN; SIMVASTATIN; STATIN;

ANGIOGRAPHY; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0035924636     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02150-6     Document Type: Article

References (37)

1. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport
2. Cholesterol and lipids in the risk of coronary artery disease: The Framingham heart study
3. Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities
4. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men?
5. Treatment of obesity: Need to focus on high risk abdominally obese patients
6. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
7. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
8. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial
9. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia
10. Micronised fenofibrate
11. A new formulation of fenofibrate: Suprabioavailable tablets
12. A comparison of the bioavailability of standard or micronized formulations of fenofibrate
13. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgian multicenter study
14. Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia
15. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7, 098 patients with dyslipidaemia
16. Micronized fenofibrate in disorders of lipid metabolism
17. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia
18. The influence of micronised fenofibrate on cardiovascular risk factors
19. Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate
20. A randomised double-blind, comparative, multinational study on lipid lowering effects of 200 mg micronised fenofibrate or 20 mg pravastatin in type II dyslipidaemic patients
21. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia
22. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia
23. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia
24. Micronized fenofibrate compared to atorvastatin in low HDL-cholesterol patients (<40 mg/dL)
25. Micronized fenofibrate or gemfibrozil in patients with combined hyperlipidaemia: A double-blind or multicentre trial
26. Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels
27. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects
28. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
29. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate
30. Mechanism of action of fibrates on lipid and lipoprotein metabolism
31. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
32. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
33. Clinical practice recommendations 2001
34. Diabetes, hyperinsulinemia, and recurrent coronary events in the VA-High-density Lipoprotein Intervention Trial (VA-HIT)